Posard Matthew L. — SEC Form 4 filings
SEC reporting owner CIK 1543792. 9 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-04-29 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 9 legs across 3 filings — 68,877 shares, $4,742,175 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 9.
- Largest priced transaction: sale of 8,896 shares @ $108.04 ($961,124) in HALOZYME THERAPEUTICS, INC., filed 2026-09-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| HALOZYME THERAPEUTICS, INC. (HALO) | Director | 6 | — | 9 legs · 68,877 sh · $4,742,175 | 6 |
| Nautilus Biotechnology, Inc. (NAUT) | Director | 3 | — | — | 3 |
Form 4 filings — Posard Matthew L.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 3,100 @ $106.13 · Sale (S): 3,000 @ $106.83 · Sale (S): 8,896 @ $108.04 · Sale (S): 4,000 @ $108.99 | EDGAR |
| 2026-06-22 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 3,796 @ $0 · Grant/award (A): 6,040 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 4,165 @ $0 · Grant/award (A): 5,750 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 10,000 @ $55.72 · Sale (S): 10,000 @ $56.19 · Sale (S): 9,881 @ $57.70 | EDGAR |
| 2024-06-17 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 10,000 @ $50.01 · Sale (S): 10,000 @ $50.62 | EDGAR |
| 2024-04-29 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 6,501 @ $0 · Grant/award (A): 8,804 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1543792 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →